| Current questions for the treatment of advanced gastric cancer A Cervantes, D Roda, N Tarazona, S Rosello, JA Perez-Fidalgo Cancer treatment reviews 39 (1), 60-67, 2013 | 197 | 2013 |
| Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients I Chirivella, B Bermejo, A Insa, A Pérez-Fidalgo, A Magro, S Rosello, ... Breast cancer research and treatment 114 (3), 479-484, 2009 | 181 | 2009 |
| Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors A Cervantes, E Elez, D Roda, J Ecsedy, T Macarulla, K Venkatakrishnan, ... Clinical cancer research 18 (17), 4764-4774, 2012 | 142 | 2012 |
| Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study J Tabernero, A Cervantes, F Rivera, E Martinelli, F Rojo, ... Journal of clinical oncology 28 (7), 1181-1189, 2010 | 129 | 2010 |
| Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer M Frasson, E Garcia‐Granero, D Roda, B Flor‐Lorente, S Roselló, ... Cancer 117 (14), 3118-3125, 2011 | 121 | 2011 |
| A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid … F Atzori, J Tabernero, A Cervantes, L Prudkin, J Andreu, ... Clinical Cancer Research 17 (19), 6304-6312, 2011 | 113 | 2011 |
| A first-in-human phase I study of the ATP-competitive AKT inhibitor ipatasertib demonstrates robust and safe targeting of AKT in patients with solid tumors C Saura, D Roda, S Roselló, M Oliveira, T Macarulla, JA Pérez-Fidalgo, ... Cancer discovery 7 (1), 102-113, 2017 | 100 | 2017 |
| Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study J Tabernero, F Ciardiello, F Rivera, E Rodriguez-Braun, FJ Ramos, ... Annals of oncology 21 (7), 1537-1545, 2010 | 92 | 2010 |
| The treatment of advanced gastric cancer: current strategies and future perspectives A Cervantes, S Roselló, D Roda, E Rodriguez-Braun Annals of oncology 19, v103-v107, 2008 | 89 | 2008 |
| Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics T Macarulla, A Cervantes, E Elez, E Rodríguez-Braun, J Baselga, ... Molecular cancer therapeutics 9 (10), 2844-2852, 2010 | 80 | 2010 |
| Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens JA Pérez-Fidalgo, S Roselló, E García-Garré, E Jordá, P Martín-Martorell, ... Breast cancer research and treatment 120 (1), 245-251, 2010 | 70 | 2010 |
| Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution … P Martin-Martorell, S Rosello, E Rodriguez-Braun, I Chirivella, A Bosch, ... British journal of cancer 99 (3), 455-458, 2008 | 70 | 2008 |
| Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer R Dienstmann, A Patnaik, R Garcia-Carbonero, A Cervantes, M Benavent, ... Cancer discovery 5 (6), 598-609, 2015 | 68 | 2015 |
| Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer F Sclafani, G Brown, D Cunningham, A Wotherspoon, LST Mendes, ... British journal of cancer 117 (10), 1478-1485, 2017 | 67 | 2017 |
| Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer N Tarazona, F Gimeno-Valiente, V Gambardella, S Zuñiga, ... Annals of Oncology 30 (11), 1804-1812, 2019 | 66 | 2019 |
| A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients … F Atzori, J Tabernero, A Cervantes, M Botero, K Hsu, H Brown, W Hanley, ... Journal of Clinical Oncology 26 (15_suppl), 3519-3519, 2008 | 63 | 2008 |
| Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines S Roselló, I Blasco, LG Fabregat, A Cervantes, K Jordan Annals of Oncology 28, iv100-iv118, 2017 | 51 | 2017 |
| The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target V Gambardella, J Castillo, N Tarazona, F Gimeno-Valiente, ... Cancer treatment reviews 86, 102015, 2020 | 46 | 2020 |
| Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase A Chakravarty, V Shinde, J Tabernero, A Cervantes, RB Cohen, EC Dees, ... Cancer research 71 (3), 675-685, 2011 | 45 | 2011 |
| Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system JAP Fidalgo, D Roda, S Roselló, E Rodríguez-Braun, A Cervantes Clinical and Translational Oncology 11 (12), 787-798, 2009 | 39 | 2009 |
